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This work, describes for the ﬁrst time, a simple biosensing design to yield an ultrasensitive electro-
chemical biosensor for a cancer biomarker detection, miRNA-155, with linear response down to the
attomolar range. MiRNA-155 was selected for being overexpressed in breast cancer.
The biosensor was assembled in two stages: (1) the immobilization of the anti-miRNA-155 that was
thiol modiﬁed on an Au-screen printed electrode (Au-SPE), followed by (2) blocking the areas of non-
speciﬁc binding with mercaptosuccinic acid. Atomic force microscopy (AFM) and electrochemical tech-
niques including cyclic voltammetry (CV), impedance spectroscopy (EIS) and square wave voltammetry
(SWV) conﬁrmed the surface modiﬁcation of these devices and their ability to hybridize successfully and
stably with miRNA-155.
The ﬁnal biosensor provided a sensitive detection of miRNA-155 from 10 aM to 1.0 nM with a low
detection limit (LOD) of 5.7 aM in real human serum samples. Good results were obtained in terms of
selectivity towards breast cancer antigen CA-15.3 and bovine serum albumin (BSA). Raw ﬂuid extracts
from cell-lines of melanoma did not affect the biosensor response (no signiﬁcant change of the blank),
while raw extracts from breast cancer yielded a positive signal against miRNA-155.
This simple and sensitive strategy is a promising alternative for simultaneous quantitative analysis of
multiple miRNA in physiological ﬂuids for biomedical research and point-of-care (POC) diagnosis.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cancer is a public health concern worldwide. One in three
women and one in two men will develop cancer during lifetime in
developed countries (Siegel et al., 2012). Early detection is the only
known approach that may improve these indicators. Traditional
diagnostic tools for breast cancer detection include: (i) clinical and
physical examinations, (ii) imaging mammography, (iii) ultrasound
magnetic resonance imaging and (iv) histopathology. Clinical and
physical examination have been shown insufﬁcient, driving pa-
tients into mammography or ultrasound studies. In turn, mam-
mography has limited sensitivity, yielding a high rate of false po-
sitive results. This approach may also lead to an accumulated ex-
posure to radiation, which is considered an additional and sig-
niﬁcant risk factor (Yahalom et al., 2013). Ultrasound is a non-in-
vasive and safe tool, but it cannot replace mammograms,B.V. This is an open access article u
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p.ipp.pt (M.G.F. Sales).especially in women above 40, and is unable to screen many of the
cancers. Histopathology is an invasive approach, of interest when
the disease is installed.
Thus, there is urgent need to develop non-invasive, simple and
low risk methods for screening/diagnosing breast cancer. Con-
sidering the high prevalence of cancer diseases and the high fre-
quency of analysis to be performed in clinical context, there is a
strong desire that such tests are made available in POC point-of-
care (POC) (Riaz et al., 2013; Grieshaber et al., 2008). Currently,
strong efforts are being developed to monitor serum biomarkers as
early detection of cancer (Mirabelli and Incoronato, 2013; Chung
et al., 2014).
In breast cancer, several serum markers may be used in clinical
practice, including carcinoembryonic antigen (CEA), carbohydrate
antigen 15–3 (CA 15–3), circulating cytokeratins, such as tissue
polypeptide antigen (TPA), tissue polypeptide speciﬁc antigen
(TPS) and cytokeratin 19 fragment (CIFRA-21-1), and the proteo-
lytically cleaved ectodomain of the human epidermal growth
factor receptor 2 (s-HER2). The most widely used serum biomarker
is CA 15-3, however, due to its lack of sensitivity at an early stage
of the disease, it cannot be used exclusively. In addition, thisnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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without clinical correlation. Also, other biomarkers like TPA and
CEA are less sensitive than CA-15.3 (Sun et al., 2012).
But recent technological advances have led to the identiﬁcation
of a new class of biomarkers named miRNAs that may lead to a
novel strategy in early cancer screening (He et al., 2015; Volinia
et al., 2012). MiRNAs contain 18–24 nucleotides in length (Johnson
and Mutharasan, 2014) and play an essential role in biological
processes such as development, cellular proliferation, apoptosis
and response to stress, and tumorigenesis. Aberrant expression
levels of miRNAs have been observed in many solid tumours, in-
cluding breast cancer (Fu et al., 2011), accounting their dysregu-
lated expression in cancer. In addition, miRNAs are stable in the
blood and have high/low expressions that can be correlated to
chemo-resistance, (Kong et al., 2010; Tavallaie et al., 2015).
In breast cancer, several studies have supported an abnormal
expression of miRNA-155 (MIR-155) in patients with the disease
(Mattiske et al., 2012). The overexpression of MIR-155 was con-
sidered as a breast cancer risk factor (Zeng et al., 2014), being
associated with clinical-pathological markers, tumour subtype,
poor survival rates, metastasis events and invasive properties of
breast cancer, as well as high tumour grade, advanced stage and
lymph node metastasis (Mattiske et al., 2012). MIR-155 is involved
in controlling several mechanisms of cell survival, cell growth,
radio/chemo-resistance (Liu et al., 2015a, 2015b; Mattiske et al.,
2012), inhibiting target genes such as FOXO3A, RhoA, and SOCS1.
The use of miRNA-155 as a potential biomarker in breast cancer
opens the possibility towards a simple serological test for prog-
nosis/diagnosis and follow-up of breast cancer under therapy.
Biosensors are today a successful route towards POC testing,
allowing fast results and a direct sample reading, without the need
for transporting samples into the laboratory (Campuzano et al.,
2014; Labib and Berezovski, 2015; Bohunicky and Mousa, 2011).
Devices relying in electrochemical transduction are currently
among the attractive biosensors reaching portability, accounting
their simplicity, sensitivity, low cost, small size, rapidity of re-
sponse, ease of use, and possibility of reading samples directly
over a wide range of concentrations (Xia and Zhang, 2014). In
general, these features of electrochemical biosensors depend of
the recognition element immobilized on the transducer, which is
responsible for interacting with the analyte in a selective mode
(Choi et al., 2010; Grieshaber et al., 2008).
In electrochemical miRNA detection, the recognition elements
are mostly linear oligonucleotide strands of DNA/RNA nature with
which the miRNA target hybridizes (Catuogno et al., 2011; Johnson
and Mutharasan, 2014; Tavallaie et al., 2015). The transduction
event measures the changes in the electrode or interfacial prop-
erties occurring upon hybridization, by means of electro-
chemically-active reporter species, including small redox mole-
cules (such as ferric species, guanine oxidation) or enzyme-sub-
strate pairs (such as horseradish peroxidase/hydrogen peroxide)
(Johnson and Mutharasan, 2014), reaching LODs typically ranging
fento-picomolar levels. Concurrent methods are mostly devoted to
biosensors using other transduction modes (optical or electro-
mechanical) or molecular-based approaches, including polymerase
ampliﬁcation, microarray (coupled to ampliﬁcation approaches),
spectroscopy, sequencing, cloning, and Northern blotting (Johnson
and Mutharasan, 2014). Biosensors with other modes of trans-
duction are typically linked to higher detection levels and mole-
cular based approaches involve complex operations that are either
expensive or far from POC requirements.
Regarding the speciﬁc electrochemical determination of miR-
NA-155, there is a limited number of works reported in the lit-
erature. The ﬁrst one was presented by Wu et al., 2013, employing
a conductive composition of Naﬁon, thionine (Thi) and Pd nano-
particles, displaying electrocatalytic activity for H2O2, to providean LOD of 1900 fM. Zhu et al., 2014, combined high base-mis-
match selectivity of ligase chain reaction with reporting probes
labelled with two different quantum dots. This elegant and com-
plex approach had an LOD ranging from 12 to 31 fM. Later, Wu
et al., 2015, presented another biosensor based on catalyzed
hairpin assembly target recycling and cascade enzymatic electro-
catalysis for signal ampliﬁcation, in a quite complex approach, to
yield an LOD of 0.35 fM. Hu et al., 2015, presented a horseradish
peroxidase and graphene quantum dots combination, this time
giving rise to a 0.14 fM LOD. Very recently, Azimzadeh et al., 2015,
proposed the modiﬁcation of a glassy carbon electrode surface by
a thiolated probe-functionalized with gold nanorods and deco-
rated on the graphene oxide material, having as reporter label
Oracet Blue. The LOD was however higher than those already re-
ported, equal to 0.6 fM. Overall, the previous attempts to produce a
sensitive device for miRNA detection have been effective but quite
complex in terms of biosensor assembly and no signiﬁcant im-
provements in terms of analytical features have been gained
within time.
Thus, a simple and low cost concurrent approach would be
appreciated, especially if a direct reading of serum samples is
rendered possible and if the biosensor assembly is set to a mini-
mum complexity by suitable optimization of critical variables. The
biorecognition element used herein is the complementary oligo-
nucleotide of synthetic origin (anti-miRNA-155) that was simply
immobilized on Au Screen printed electrodes (Au-SPE). Non-spe-
ciﬁc binding was blocked with mercaptosuccinic acid modiﬁcation,
for subsequent hybridization of the anti-MIR with the target
analyte, MIR-155. All studies regarding the chemical modiﬁcation
and optimization of the biosensor design, electrical characteriza-
tion, and analytical application are presented herein.2. Experimental section
2.1. Apparatus
The electrochemical measurements were performed with a
potentiostat/galvanostat from Metrohm Autolab, PGSTAT320N,
controlled by NOVA 1.11 software. The gold-screen printed elec-
trodes (Au-SPEs) were purchased from DropSens (DS-C220AT),
built with (i) a counter electrode made of gold; (ii) a reference
electrode and electrical contacts made of silver; and (iii) a gold
working electrode with 4 mm diameter. Also, the Au-SPEs were
interfaced in a switch box from DropSens, allowing their connec-
tion to the potentiostat.
UV/Vis studies were made in the spectrophotometer Evolution
220 UV–visible from Thermo Scientiﬁc. AFM studies were made in
a Nanoscope IVA from Veeco Metrology Multimode.
2.2. Reagents
The water was ultrapure Mili-Q laboratory grade (conductivity
o0.1 mS/cm) or autoclaved with 0.1% diethylpyrocarbonate (DEPC)
in order to increase stability of the miRNA by decreasing RNase
activity.
All reagents were used without further puriﬁcation. Potassium
hexacyanoferrate-III (K3[Fe(CN)6]), potassium hexacyanoferrate-II
(K4[Fe(CN)6]) trihydrate, magnesium chloride (MgCl), and sodium
phosphate (Na2HPO4), were from Riedel-deHaen; Serum cornay
human was from PZ CORMAY S.A., Poland; Phosphate buffer saline
(PBS) and bovine serum albumin (BSA) were from Amresco; Cal-
cium chloride (CaCl2) and potassium chloride (KCl) from Merck;
Ethylenediamine tetraacetic acid (EDTA) from BDH; Sodium
chloride (NaCl) and absolute ethanol (99.5%) from Panreac; Hy-
droxymethyl-aminomethane (Tris) from Fisher BioReagents;
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dithiothreitol (DTT), mercaptosuccinic acid (MSA, 97%), DEPC, and
cancer antigen 15–3 (CA-15.3) from Sigma.
The oligonucleotide probes were anti-miRNA-155 (com-
plementary strand that was thiol modiﬁed and with adenine
spacers) and miRNA-155, puriﬁed by HPLC and obtained from the
Metabion. The sequences were as follows: anti-miRNA-155 (anti-
miRNA155), 5′-HS-AAA AAA AAC CCC UAU CAC GAU UAG CAU
UAA-3′; miRNA-155 (miRNA-155), 5′-UUA AUG CUA AUC GUG AUA
GGG GU-3′.2.3. Solutions
All solutions were prepared in ultrapure water, autoclaved with
0.1% DEPC. The stock solution of oligonucleotide (1.16 mg/ml, anti-
miRNA) was prepared in SSPE buffer containing 0.02 M EDTA,
2.98 M NaCl and 0.2 M phosphate buffer (20 diluted, pH 7.4).
The stock solution of 0.6 mg/mL of miRNA-155 was prepared in
Tris–HCl, containing 0.02 M Tris, 0.14 M NaCl, 0.001 M MgCl2,
0.005 M KCl and 0.001 M CaCl2 (pH 7.4). Less concentrated stan-
dards were obtained by accurate dilution of the previous solution
in 0.01 M Tris buffer containing 0.001 M EDTA and 0.05 M NaCl
(pH 7.4). The immobilization and hybridization buffer were pre-
pared in the same buffer solution. The buffer for regeneration
(SSC) contained 3.0 M NaCl and 0.3 M trisodium citrate
(0.1diluted, pH 7.4).
Solutions of interfering species (for selectivity study) were
prepared in the same buffer used in the immobilization and hy-
bridization stages. The concentration of miRNA-155 was set to
0.6 mg/ml and the interfering species were BSA (0.30 mg/ml) and
CA-15.3 (30 U/mL). The miRNA-155 solutions were prepared in
real human serum (Cornay Human Serum), 1000diluted. The
electrochemical studies were made in a solution of 5.0103 M of
K3[Fe(CN)6] and 5.0103 M of K4[Fe(CN)6] redox probe, pre-
pared in PBS buffer, pH 7.4.
2.4. Preparation of electrochemical biosensor on Au-SPE
Before modiﬁcation, the working Au-SPE surface was cleaned
by washing with absolute ethanol, followed by CV electrochemical
treatment with 0.5 M H2SO4, for 10 cycles (500 mV/s; 0.1 to
1.5 V). Finally, the Au surface was washed with ultrapure water to
ensure the removal of unwanted chemical species.
The synthesis of the biosensor was made in two steps. Step
(1) consisted in incubating anti-miRNA-155 (1 mmol/mL) with DTT
(0.1 M) on the Au-SPE working area. The probe solution was pre-
pared in buffer of pH 7.4 that contained Tris, EDTA and NaCl,
previously heated at 90 °C for 5 min, and incubated for 2 h at room
temperature. The electrode surface was then washed with ultra-
pure water several times. In step (2), the non-speciﬁc binding
areas were blocked by incubating the sensory surface with
0.002 mg/mL MSA, for 2 h, at room temperature. The hybridization
of the probe with the target miRNA-155 was made with several
miRNA-155 standards solutions, prepared in buffer or in blank
sera. Each standard was incubated for 30 min at 37 °C.2.5. UV characterization
The hybridization stage occurring between probe and target
miRNAwas followed by UV–vis spectrophotometry. It was done by
measuring the spectral data of each individual solution (Anti-
miRNA-155, miRNA-155; and mixture of both) in the spectral
range from 220 to 300 nm.2.6. AFM analysis
The morphological analysis of biosensor was performed by
AFM in tapping mode. These studies were conducted on planar Au
surfaces employed in regular surface plasmon resonance (SPR)
measurements. For this, anti-miRNA-155, Anti-miRNA-155/MSA
and anti-miRNA-155/MCA/miRNA155 materials were assembled
on SPR planar gold chips following the same procedure as that
described for the Au-SPEs. The analysis of AFM images were col-
lected and handled by the nanoscope software, coupled to the
same equipment.
2.7. Electrochemical procedures
All electrochemical assays were conducted in triplicate. CV
assays were made for scanning potentials from 0.5 to þ0.5 V, at
a scan-rate of 50 mV/s. EIS assays were performed at an open
circuit potential, using a sinusoidal potential perturbation with an
amplitude of 0.01 V, and 50 data points, logarithmically dis-
tributed over 0.1–100,000 Hz frequency range. The EIS data was
ﬁtted into a Randles equivalent circuit, using 1.11 Nova Software
from Autolab. SWV assays were conducted for a potential range
from 0.2 to þ0.8 V, with a frequency of 25 Hz and a step height
of 50 mV.
The electrical properties of modiﬁed surfaces were followed-up
by CV, EIS and SWV assays, carried out in a redox probe solution of
5.0103 M of [Fe(CN)6]3 and 5.0103 M of [Fe(CN)6]4 ,
prepared in PBS buffer, pH 7.4. Calibration curves used EIS and
SWV assays and included standard solutions of miRNA-155, pre-
pared in Tris buffer pH 7.4 (ranging from 1.0 fM to 10 nM), or in
human serum (ranging from 0.01 aM to 10 nM). The LOD was
calculated as Xþ3s, where X was the average value of the EIS or
SWV blank signals (obtained in the absence of miRNA-155) and s
the known standard deviation of EIS or SWV blank signal con-
secutive readings (Harvey, 2000).
Selectivity studies were conducted by competitive assay be-
tween miRNA-155 with two different biomolecules that can be
found in biological ﬂuids, such as BSA (0.30 mg/mL) and CA-15.3
(30 U/mL).
2.8. MiRNA-155 assay
The performance of the biosensor was analysed by the standard
addition method, in order to determine the miRNA-155 con-
centration in spiked human blank serum. MiRNA-155 concentra-
tions in samples were set to different levels, equal to 100 fM and
100 pM, always lying within the linear range of the device. The
human serum was diluted in TRIS buffer. All the assays were
conducted in duplicate and analytical data was collected in EIS.3. Results and discussion
3.1. Biosensor assembly
The schematic construction of the miRNA-155 biosensor is
shown in Fig. 1, and involved three main stages: (1) Au-SPE pre-
treatment; (2) oligonucleotide immobilization and (3) non-speciﬁc
binding blockage. The miRNA-155 hybridization assay was the ﬁ-
nal approach made with the biosensor, and concerned the analy-
tical stage.
Initially, Au-SPEs were cleaned ﬁrst by washing with ethanol,
two times, and after by electrochemical cleaning, making use of
consecutive CV assays in a H2SO4 solution. This oxidative stage
allowed the oxidation of any organic species allocated on the
surface and improved the electrochemical properties of the bare
Anti – miRNA-155
Immobilization of
Anti-miRNA-155
S S S
NH2 NH2 NH2
MSA 
Blocking non-specific binding
S S S
NH2 NH2 NH2
Binding of miRNA-155
miRNA -155
S S S
NH2 NH2 NH2
LEGEND
Gold
NH2
Anti – miRNA-155
miRNA-155Non-specific binding
A B
C
Fig. 1. Schematic illustration of electrochemical biosensor for detection of miRNA-155. (A) Immobilization of Anti-miRNA155 on gold surface; (B) Blocking the non-speciﬁc
binding; and (C) Hybridization with miRNA-155. The corresponding 3D AFM images are top views of (A) Au-SPR (B) Au-SPR/Anti-miRNA-155 and (C) Au-SPR/Anti-miRNA-
155/miRNA-155.
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redox probe and increasing peak currents.
The probe was then covalently bond to the clean SPE by in-
cubating the Au working electrode in a solution of anti-miRNA-155
with a thiol group at its 5’end, in a hydrated chamber, at room
temperature, and for a set time period. (Fig. 1A). The probe had
several consecutive adenine nucleotides between the –SH end and
the complementary sequence to miRNA-155, acting as spacer and
conferring mobility to the probe (in order to reduce steric hin-
drance at the hybridization stage). Before incubation, the anti-
miRNA155 probe was treated with 0.10 M DTT for 15 min, in order
to disrupt disulphide bonds, and warmed at 90 °C for 5 min to
ensure that the strand had a linear pattern. This last heating stage
was found crucial, as without it the amount of immobilized probe
was much smaller (less than 10%) and irreproducible.
Next, the non-speciﬁc binding was blocked with MSA (Fig. 1B).
This compound has an –SH bond allowing its covalent binding to
free Au areas existing on the working electrode. This stage was
fundamental to avoid the direct interaction between any biomo-
lecule in a sample and the gold.
The analytical event involved the hybridization between the
probe and miRNA-155. It was made by incubating the working
electrode area with different concentrations of target miRNA
(Fig. 1C). The different standard solutions were incubated on the
working Au-SPE surface at 37 °C, for a set amount of time.
The relevant data regarding the morphological characterization
of the biosensor and the UV analysis (please see Fig. S1, conﬁrmingthe hybridization between anti-miRNA-155 and miRNA-155) is
presented and discussed in the Supplementary section (identiﬁed
as S1 and S2).
3.2. Electrochemical follow-up of the gold surface modiﬁcations
The chemical modiﬁcation of the Au-SPE surface produced al-
terations in its electrical features, evaluated by monitoring the
electron transfer properties of a standard redox system. Different
redox systems were tested for this purpose (Ruthenium and Iron),
prepared in different buffer conditions. A redox probe of [Fe
(CN)6]4/[Fe(CN)6]3 was selected, at pH 7.4, as the electrical
changes monitored under these conditions generated more sen-
sitive alterations at the detected signal. The electrochemical ap-
proaches used for this purpose were CV, EIS and SWV assays and
the corresponding data is shown in Fig. 2.
CV analysis is shown in Fig. 2A. When compared to the clean
surface, the Au-SPE modiﬁed with anti-miRNA and MSA showed
increased peak-to-peak potential separation and decreased
cathodic/anodic peak currents. This accounted an increased
charge-transfer resistance at the Au-SPE surface after each mod-
iﬁcation stage. After hybridization with miRNA-155 (Au-SPE/Anti-
miRNA155/miRNA-155), the peak current decreased more, and a
slight shift was observed in the peak potentials, thereby con-
ﬁrming the occurrence of chemical changes.
The corresponding EIS measurements are shown in Fig. 2B and
were consistent with CV data. Randle's equivalent circuit was used
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Fig. 2. Electrochemical assays for controlling the gold surface modiﬁcation, in 5.0103 M [Fe(CN)6 ]3 and 5.0103 M [Fe(CN)6]4 , solution, prepared in in buffer (TRIS
with EDTA and NaCl). CV (A), EIS (B) and SWV (C) assays.
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surface and EIS spectra were represented as Nyquist plots – in-
cluding a semicircle, in which the diameter corresponded to the
electron transfer resistance (Rct) (Panagopoulou et al., 2010) and
the linear part represented a diffusion limited process (Suni,
2008). The Randle's equivalent circuit included several elements,
in which the high frequency region is dominated by the double
layer capacitance (Cdl) and the magnitude of the electrolyte so-
lution resistance (Rs) (Liu et al., 2010); the charge-transfer re-
sistance (Rct), which is inversely proportional to the rate of elec-
tron transfer; and the Warburg diffusion element (W) at higher
frequencies, accounting for the diffusion of ions. Overall, the bare
gold electrode showed a straight line or very small semicircle
domain, which suggested a mass diffusion limiting step of the
electron transfer process. After, the immobilization of thiol-based
materials on the clean Au-SPE, the diameter of the semicircle of
the Nyquist plot increased considerably. This observation was
consistent with an increased electron transfer resistance at the
surface, enhanced by the fact that the single strand anti-miRNA155
was negatively charged through its phosphate backbone, thereby
hampering the electrode transfer event of a negatively charged
redox couple (Wu et al., 2015). The hybridization of the probe with
miRNA-155 also increased the Rct values, thereby conﬁrming its
effect upon the electron transfer and the increased density of
negative charges occurring at the surface.
SWV data is presented in Fig. 2C and is also consistent with EIS
and CV assays. As it is more sensitive than CV, the changes in
electrical transfer properties of the several modiﬁcation stages
were more evident in SWV. Voltammograms indicated a decrease
in peak current for assembly and hybridization events.
Overall, CV, EIS and SWV assays were consistent, and conﬁrmed
the occurrence of chemical changes at the gold surface, both at the
biosensor assembly and at the hybridization event. From a prac-
tical point of view, EIS and SWV techniques seemed more sensitive
to the hybridization event, being therefore selected for the sub-
sequent analytical application.
3.3. Analytical performance of miRNA sensor
The analytical performance of the biosensor was evaluated by
calibration curves in EIS and SVW measurements. For this, in-
creasing concentrations of miRNA-155 were incubated at the
surface for a speciﬁc amount of time, and the resulting Rct (in EIS)
or current intensity (I, in SWV) values obtained with the iron re-
dox probe measured against logarithm of miRNA-155concentration. It is important to highlight that several variables
were evaluated and optimized, including concentration, tem-
perature and time given for the incubation of anti-miRNA solution
on the clean gold surface, time and temperature given for the
hybridization stage, buffer composition, etc.. The analytical data
presented next regards only the best conditions selected.
In general, EIS (Fig. 3A) measurements showed that increasing
concentrations of miRNA-155 increased the electrical resistance of
the surface, as the diameter of the semicircles in the Nyquist plots
increased. The linear plot was made between logarithm Rct and
logarithm of miRNA-155 concentration. The response of the bio-
sensor in EIS was tested in three calibrations, made with in-
dependent sensors, in different days, and was found highly re-
producible. All these showed a linear trend between 1.0 fM and
100 pM. As may be seen in Fig. 3B, the second and third calibra-
tions had an average slope of 0.086 log Ω/decade, with a standard
of deviation 2.2%. The squared correlation coefﬁcient of all cali-
brations was always 40.99, and the average limit of detection was
0.54 fM.
SWV assays also showed linear plots, but this time between
current intensity (I, in SWV) and logarithm of miRNA-155 con-
centration. The linear behaviour was observed from 1.0 fM and
10 nM (Fig. 3C). The increasing miRNA-155 concentrations were
revealed by the decreasing peak currents of redox probe solution.
The following calibrations are presented in Fig. 3D, showing
average slopes of 25.18 mA/decade and square correlation
coefﬁcients 40.99. The standard of deviation of the these assays
was 0,5% (Fig. 3D), and the limit of detection was 2.8 aM.
Overall, the assembled biosensor showed consistent, sensitive
and reproducible calibration curves, both in EIS and in SWV assays.
The obtained results suggested that the biosensor displayed a
highly selective and sensitive response against miRNA-155.
3.4. Regeneration of Au-SPE
The regeneration of a biosensor after a calibration assay maybe
achieved by several physical (enthalpic interaction, entropic in-
teractions, thermal regeneration-temperature) and chemical (acid/
base-mediated regeneration, detergents, glycine, urea and another
buffers) approaches (Goode et al., 2014). In this work, physical
(temperature) and/or chemical (buffer treatment) assays were
tried out and the results presented in Fig. 4.
The temperature was considered as an important parameter to
be tested herein since the 3D structure of oligonucleotides is ty-
pically temperature-dependent. A temperature increase leads to
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forces to be overcome after reaching the suitable temperature. The
ﬁrst assay was made by heating the Au-SPE up to 90 °C, the same
temperature that ensured previously that the anti-miRNA-155 was
linear and free to hybridize. The 90 °C is indeed the typical de-
naturation temperature used in PCR (Polymerase chain reaction)
assays, for which no irreversible denaturing or decoupling of oli-
gonucleotide base pairs would be expected (Champaign, 2013).
After 90 °C for 5 min, only little alterations were detected
compared to the original signal of the biosensor before its hy-
bridization: little shift in CV peaks; (Fig. 4A); little decrease of the
EIS resistance (Fig. 4B); and a little increase of the peak current in
SWV. Still, the small changes observed in the reused Au-SPE/anti-
miRNA155 biosensor seemed to be related to the silver reference
electrode modiﬁcation/oxidation, promoted by such a high tem-
perature (Fig. 4C). This alteration was visually perceptible.Thus, further assays were tested at lower temperature, in
conjunction with a chemical buffer. For this, the hybridized bio-
sensor was incubated in a saline-sodium citrate buffer (SSC) di-
luted 10 at 60 °C. After this, the signal of the regenerated surface
matched exactly that of the original biosensor, in all electro-
chemical techniques (Fig. 4, D, E and F).
After recovering the original signal, the reused biosensor was
calibrated again to evaluate its behaviour under a second calibra-
tion, and further on in a third calibration. This was made to test
the ability of the complementary oligonucleotides remaining on
the surface to hybridize with its target miRNA (because staying
there would not grant its ability to hybridize). The calibration as-
says were made by EIS and SWVmeasurements again, and showed
very similar analytical features to the original biosensor, calibrated
by its ﬁrst time.
In EIS assays, the linear range was observed between 1.0 fM and
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concentration (Fig. S2). The slope was 0.0793 log Ω/decade in the
second calibration and changed to 0.0786 log Ω/decade in the
third calibration, while the intercept was 4.1554 log Ω in the sec-
ond calibration and changed to 4.1364 log Ω in the third calibra-
tion. The standard deviation of the slope and intercept of all three
calibrations performed in the same device was 5.2% and 0.3%,
meaning that the biosensor is able to generate reproducible cali-
brations after regeneration. Indeed, it is possible that the re-
generation process has a little (but not relevant) impact on the
biosensor response, as the standard deviation between second and
third calibrations is much smaller (equal to 0.6% and 0.3%,
respectively).
In SWV assays the calibration was also recovered in terms of
concentration range, but the variability within the three calibra-
tions was higher. The slope of the second calibration was
26.387 μA/decade and changed to 31.929 μA/decade in the
following calibration, while the intercept was 201.5 μA and
changed to 257.6 μA. The standard deviation of the slope and in-
tercept of the three calibrations (ﬁrst and two regenerated) was
9.5% and 16.0%, which was clearly high, when compared with the
EIS assays.
Overall, the biosensor may be regenerated after contacting with
miRNA concentrations up to 100 nM, provided that the suitable
approach is taken. In addition, EIS studies seem more reliable, if
the Au-SPE is to be reused after its ﬁrst calibration. This is parti-
cularly suitable for making the complete analytical procedure with
a single chip (which may include calibration and sample analysis,
all in a single device).3.5. Selectivity
The selectivity study was conducted by evaluating the effect of
chemical compounds present in biological ﬂuids. A competitive
assay was selected for this purpose. This was done by testing a
solution of 10 pM miRNA-155 as single analyte and also in con-
junction with other common biomolecules in serum, keeping the
same concentration of miRNA-155. The incubation time was set to
30 min, the same period of time used in the calibration.
The interfering compounds studied were CA-15-3 (protein
biomarker that in breast cancer condition co-exists with miRNA-
155 in serum) and BSA (highly concentrated protein in serum of
normal/diseased person). These species were tested within their
physiological levels. The % average deviation produced by each
interfering species in pure miRNA-155 solutions was þ3.8% when
CA-15.3 was present and 5.2% when BSA was added (Fig. S3).
These assays were performed in triplicate using the same Au-SPE,
accounting its reliability after regeneration in EIS measurements.
An extract from cell lines of melanoma was also tested herein.
Melanoma is another cancer disease where miRNA-155 is not ex-
pected to exist, at least in signiﬁcant levels. The extract was ob-
tained by membrane cell disruption and simple ﬁltration. The
obtained signal was almost coincident to the blank (Fig. 6B),
therefore indicating that no signiﬁcant interference would be ex-
pected by applying this biosensor to control real cell lines culture.
Overall, no signiﬁcant interferences were observed in these
selectivity tests, neither from single analytes nor with complex
real cell extracts.
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The application of the biosensor to real samples was made after
calibrating in standard solutions prepared in blank serum, instead
of the buffer used until now. The analytical features of the re-
sulting calibration curves in EIS and SWV (Fig. 5) were also eval-
uated at this stage.
As before, EIS calibration curves plotted logarithm Rct (in EIS)
against logarithm miRNA-155 concentration. In general, the cali-
brations showed good analytical features in terms of lower con-
centration of linear range, LOD and slope (10 aM, 5.7 aM,
0.082 log Ω/decade) respectively (Fig. 5A and B). Compared to the
calibrations made with standard solutions prepared in buffer, this
novel condition of preparing standards in serum had no signiﬁcant
impact in the slope (within the previous standard deviation).However, and interestingly, the use of standard solutions in buffer
widened the concentration range producing a linear response. The
biosensor provided linear responses down to 10 aM with lower
LODs than before. The calibrations in SWV showed a similar be-
haviour (Fig. 5C), with a decrease in the lower limit of linear range
and LOD and a slope increase (1 aM, 0.18 aM, 36 mA/decade,
respectively).
For sample analysis, real human serum serving as blank was
spiked with miRNA-155 in two different concentrations: 100 fM
and 100 pM. This was performed in triplicate and only by fol-
lowing EIS data. The calibration data used in the analysis to cal-
culate the concentrations in the spiked serum was the one pro-
vided by the same biosensor before regeneration. Comparing ad-
ded and found amounts, the relative errors obtained were 6.9%
and 7.2%, respectively. Overall, the results were found accurate in
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of control human serum of healthy individual.
Extracts from cell-lines MCF-7 from breast cancer disease were
also analysed, yielding a positive signal against miRNA-155, as
expected. This sample was analysed by serial dilution in buffer,
diluting 1000 and 10 times the raw extract and reading
without further treatment, starting by its lower concentration. The
results are presented in Fig. 6A, showing a proportional behaviour
within the several dilutions. The obtained values conﬁrmed the
high precision of this new method, even when different dilution
levels are combined. The average concentration of miRNA-155 in
the cell extract was 1.021011 mol/L, with a standard deviation
of 8.711013 mol/L that corresponded to a relative standard
deviation of 8.6%.4. Conclusions
This work described the development of a highly sensitive and
inexpensive biosensor for the rapid detection of the emerging
cancer biomarker miRNA155, in serum. The biosensor assembly
was very simple and effective, being temperature a critical step.
From the analytical perspective, the biosensor was able to detect
very low concentrations of miRNA-155, down to 1–10 aM in a
serum background. This was a very important feature of this bio-
sensor, because it allows a higher degree of sample dilution and
therefore surpassing the interference of any unexpected/unwanted
biomolecule resulting from an abnormal physiological condition.
In addition, the device could be reused along consecutive readings
of new solutions, most especially in EIS readings, while showing
excellent selectivity towards other proteins in biological ﬂuids and
cell extracts from another cancer disease.
This simple and sensitive strategy is considered a promising
approach for the simultaneous quantitative analysis of multiple
miRNA-155 in physiological ﬂuids, in biomedical research and POC
diagnosis. This device is also appropriate to integrate a multi-panel
biomarker reading that includes the traditional CA15-3 biomarker,
as this protein did not interfere with the analytical readings of the
device.
In addition, this device opens new horizons into real time
monitoring of miRNA cancer biomarker in clinical context, also
taking advantage of its ability de-hybridize and allowing its re-
using in an on-line sensor approach.Acknowledgements
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